论文部分内容阅读
制药公司可以通过药物经济学(PE)研究来定量一个具体药物的总体临床试验的、经济学的和人道主义的影响。这些资料将成为企业制订推进市场接受这个药物的战略计划的一部分。虽然药物经济学研究数据资料本身并不是药物审批所要求的(如在美国),但展现药物经济学价值在促使第三方为药品提供补贴、在获得管理部门批准其各种权利要求(如适应证、剂型、强度/规格、定价等)、在帮助市场开拓或扩展以及在使医疗保健提供者和病人相信新治疗药比现有的药物效益更明显等
Pharmaceutical companies can quantify the overall clinical, economic, and humanitarian impact of a given drug through pharmacoeconomic (PE) studies. This information will be part of a strategic plan for companies to develop markets that will embrace the drug. Although pharmacoeconomic data are not themselves required by drug approvals (as in the United States), demonstrating the value of pharmacoeconomics is forcing third parties to subsidize drugs, obtaining regulatory approval of their various claims (eg, indications , Dosage forms, strength / specifications, pricing, etc.), helping to open up or expand the market and convincing healthcare providers and patients that new therapeutics are more effective than existing ones